Display options
Cite
Chiari EF, Weiss W, Simon MR, et al. Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection. J Infect Dis. 2021;224(8):1394-1397doi: 10.1093/infdis/jiab087.
Chiari, E. F., Weiss, W., Simon, M. R., Kiessig, S. T., Pulse, M., Brown, S. C., Gerding, H. R., Mandago, M., Gisch, K., & von Eichel-Streiber, C. (2021). Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection. The Journal of infectious diseases, 224(8), 1394-1397. https://doi.org/10.1093/infdis/jiab087
Chiari, Estelle F, et al. "Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection." The Journal of infectious diseases vol. 224,8 (2021): 1394-1397. doi: https://doi.org/10.1093/infdis/jiab087
Chiari EF, Weiss W, Simon MR, Kiessig ST, Pulse M, Brown SC, Gerding HR, Mandago M, Gisch K, von Eichel-Streiber C. Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection. J Infect Dis. 2021 Oct 28;224(8):1394-1397. doi: 10.1093/infdis/jiab087. PMID: 33588433; PMCID: PMC8557658.
Copy Download .nbib Format: NLM
Share it on

J Infect Dis. 2021 Oct 28;224(8):1394-1397. doi: 10.1093/infdis/jiab087.

Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection.

The Journal of infectious diseases

Estelle F Chiari, William Weiss, Michael R Simon, Stephan T Kiessig, Mark Pulse, Stephen C Brown, Hanne R Gerding, Maurice Mandago, Karina Gisch, Christoph von Eichel-Streiber

Affiliations

  1. Secretory IgA, Inc, Ann Arbor, Michigan, USA.
  2. Preclinical Services, University of North Texas Health Science Center-College of Pharmacy, Fort Worth, Texas, USA.
  3. Allergy and Immunology Section, William Beaumont Hospital, Royal Oak, Michigan, USA.
  4. Department of Medicine, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.
  5. Departments of Internal Medicine and Pediatrics (Clinical Emeritus), Wayne State University School of Medicine, Detroit, Michigan, USA.
  6. PreviPharma, GmbH, Mannheim, Germany.
  7. tcgBIOMICS, GmbH, Bingen, Germany.

PMID: 33588433 PMCID: PMC8557658 DOI: 10.1093/infdis/jiab087

Abstract

Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg × 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID × 21 days) or hyperimmune sIgA/monomeric IgA (BID × 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P = .018 and .039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Keywords: Clostridioides difficile infection; immunotherapy; secretory IgA

References

  1. J Pediatr. 1991 Apr;118(4 Pt 1):633-7 - PubMed
  2. Transfus Med Hemother. 2011;38(1):65-70 - PubMed
  3. Anaerobe. 2016 Oct;41:91-103 - PubMed
  4. J Am Chem Soc. 1946 Mar;68:459-75 - PubMed
  5. Diagn Microbiol Infect Dis. 1994 Apr;18(4):205-9 - PubMed
  6. Int J Mol Sci. 2020 Dec 04;21(23): - PubMed
  7. J Immunol Methods. 1998 Mar 15;212(2):193-211 - PubMed
  8. Mucosal Immunol. 2011 Nov;4(6):603-11 - PubMed
  9. Immunity. 2002 Jul;17(1):107-15 - PubMed
  10. N Engl J Med. 2000 Feb 10;342(6):390-7 - PubMed
  11. J Biol Chem. 2013 Feb 8;288(6):4085-94 - PubMed
  12. Lancet. 2001 Jan 20;357(9251):189-93 - PubMed

Publication Types

Grant support